Danazol
Danazol, sold as Danocrine and other brand names, is a medication used in the treatment of endometriosis, fibrocystic breast disease, hereditary angioedema and other conditions. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Danatrol, Danocrine, Danol, Danoval, others |
Other names | WIN-17757; 2,3-Isoxazolethisterone; 2,3-Isoxazol-17α-ethynyltestosterone; 17α-Ethynyl-17β-hydroxyandrost-4-en-[2,3-d]isoxazole |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682599 |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid; Progestogen; Progestin; Antigonadotropin; Steroidogenesis inhibitor; Antiestrogen |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Saturable with dosage, higher with food intake |
Protein binding | To albumin, SHBG , CBG |
Metabolism | Liver (CYP3A4) |
Metabolites | • 2-OHM-Ethisterone • Ethisterone |
Elimination half-life | Acute: 3–10 hours Chronic: 24–26 hours |
Excretion | Urine, feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.503 |
Chemical and physical data | |
Formula | C22H27NO2 |
Molar mass | 337.463 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(verify) |
The use of danazol is limited by masculinizing side effects such as acne, excessive hair growth, and voice deepening. Danazol has a complex mechanism of action, and is characterized as a weak androgen and anabolic steroid, a weak progestogen, a weak antigonadotropin, a weak steroidogenesis inhibitor, and a functional antiestrogen.
Danazol was discovered in 1963 and was introduced for medical use in 1971. Due to their improved side-effect profiles, particularly their lack of masculinizing side effects, danazol has largely been replaced by gonadotropin-releasing hormone analogues (GnRH analogues) in the treatment of endometriosis.